NEK2 and nasopharyngeal carcinoma: In summary, for the first time, we demonstrated that expression of NEK2, which is located in the frequently amplified +1q32‐q33 region, increases at the advanced clinical stages (stage III‐IV) and paired recurrence of NPC.